BioSpace News Archive

NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”) today announced plans to issue an important update on discussion the company is having regarding strategic partnerships, including Timeline for the company’s Phase 3 program in narcolepsy.

MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced that study data shows THIO’s potent anticancer activity in Diffuse Intrinsic Pontine Glioma (DIPG), one of the most aggressive tumors affecting the central nervous system in children.

Foundation Medicine Inc. announced that it has received approval from the U.S. Food and Drug Administration for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation.

Mindray, a global leader and developer of healthcare solutions and technologies in ultrasound, patient monitoring, and anesthesia, announced a new milestone in their cooperative agreement with Edwards Lifesciences, a global leader in medical innovations for structural heart disease and critical care monitoring.

UCB, a global biopharmaceutical company, today announced the first analyses of pooled data from the two Phase 3 bimekizumab studies (BE HEARD I and BE HEARD II) in moderate-to-severe hidradenitis suppurativa (HS).

ona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”), a nanotechnology life sciences company with proprietary manufacturing technology for biocompatible gold nanorods (“GNRs”), is pleased to provide an update on the status of its current operating activities

Madrigal Pharmaceuticals, Inc. announced that the company granted equity awards to seven new employees with a grant date of October 10, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company’s 2023 Inducement Plan.

Sight Sciences, Inc. announced the presentation of the full phase I results from the SAHARA randomized controlled trial.

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced initial clinical data for RLY-4008 (lirafugratinib) in patients with FGFR2-altered solid tumors.

Researchers found that removing as much tumor as possible in multiorgan metastatic colorectal cancer—via various methods—did not cause a decrease in quality of life despite an increase in adverse events; survival benefits remain unclear.